Where does OCRA's clinical trial data come from?

OCRA indexes clinical trials from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Trials are matched to diseases, investigators, and funded research tracked across the platform.

How do I find clinical trials for ovarian cancer?

Search by condition, treatment type, trial phase, or NCT identifier. Each trial page shows current status, eligibility criteria, study locations, and a direct link to the ClinicalTrials.gov source record.

How often is clinical trial data updated?

Trial data is refreshed through periodic ingestion from the ClinicalTrials.gov v2 API. Status changes, new enrollments, and newly registered trials are captured during each update cycle.

Follow-up of Cell Changes in the Cervix

NCT05709730Active, Not RecruitingOBSERVATIONAL

Summary

The purpose of the study is to follow up on cell changes detected in the cervical cancer screening program, to investigate whether they are handled with adequate quality.

Key Facts

Lead Sponsor

Karolinska University Hospital

Enrollment

885

Start Date

2016-07-07

Completion Date

2019-12-31

Study Type

OBSERVATIONAL

Official Title

Follow-up of Cell Changes in the Cervix

Interventions

HPV genotyping

Conditions

Cancer of Cervix

Eligibility

Age Range

23 Years – 80 Years

Sex

FEMALE

Inclusion Criteria:

* women with an AGC diagnosis between February 17, 2014 and December 31, 2018
* 23-80 years old
* resident of the Stockholm-Gotland region of Sweden

Exclusion Criteria:

\-

Outcome Measures

Primary Outcomes

cervical intraepithelial neoplasia 3 (CIN3+)

Risk for developing CIN3+ or worse depending on HPV type

Time frame: 2014-2018

Locations

Karolinska University Hospital, Stockholm, Sweden

Linked Papers

2022-08-27

Atypical glandular cells and development of cervical cancer: Population‐based cohort study

AbstractThe effect of cervical screening on cervical adenocarcinoma has been variable, possibly because the risk associated with the precursor atypical glandular cells (AGC) is not well known. A cohort of all 885 women in the capital region of Sweden with AGC, a concomitant human papillomavirus (HPV) analysis, and a histopathology was followed until 2019. Cumulative incidence proportions of cervical intraepithelial lesion grade 3 or worse (CIN3+) by HPV type was determined by 1‐Kaplan‐Meier estimates. Hazard ratios (HR) for CIN3+ or for invasive cancer were estimated with Cox regression. After 2 years of follow‐up, the cumulative incidence proportions of CIN3+ were 80% (95% confidence interval [CI]: 74‐86%), 58% (95% CI: 50‐60%) and 10% (95% CI: 5‐18%) among HPV16/18 positive, “other HPV” positive and HPV‐negative women, respectively. Among the 300 women with HPV16/18 positive AGC, 217 developed CIN3+ of which 35 were invasive cervical cancer. The 2‐year cumulative invasive cancer risk for HPV16/18 positive AGC was 17% (95% CI: 12‐24%). Primary HPV‐screening had a similar yield of CIN3+ as cytology screening, albeit HPV‐negative AGC is by design not detected by HPV screening. Among 241 women with HPV‐negative AGC, 11 developed CIN3+ mostly after clinically indicated samples. We found no significant risk differences depending on age or sampling indication. The low CIN3+ risk after HPV‐negative AGC implies safety of primary HPV screening. The high risk of invasive cervical cancer after HPV16/18 positive AGC implies that management of this finding is a priority in cervical screening.

Linked Investigators

Joakim Dillner